True to its name, Orchestra BioMed is currently conducting a symphony of several business ventures at once.
In a three-in-one announcement Tuesday, the Pennsylvania-based startup unveiled a new partnership with Medtronic, the close of its latest funding round and—backed in part by the proceeds from that financing—plans to go public through a SPAC merger.
Read the full article at: www.fiercebiotech.com
